The Ebola virus devastated west Africa in 2014, claiming over 11,000 lives in Sierra Leone, Liberia and Guinea.

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

Merck makes Ervebo, which is the first Ebola vaccine approved by the U.S. Food and Drug Administration. In 2019, the vaccine was approved in the U.S. for use in people ages 18 and older.

The vaccine rVSVΔG-ZEBOV-GP (Ervebo) not only reduces the risk for Ebola infection but also halves mortality rates. This is the result of a study published in The Lancet Infectious Disease.

Ebola vaccine cuts fatality even ... showed that the risk of dying of Ebola was halved among people who had been vaccinated with a single dose of Merck’s Ervebo before developing symptoms ...

At his laboratory at the University of Hawaii John A. Burns School of Medicine in Honolulu, researcher Axel Lehrer has several vaccine candidates that potentially could save lives around the globe.

The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...

The Ebola virus devastated west Africa in 2014, claiming over 11,000 lives in Sierra Leone, Liberia and Guinea.

The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...